Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Thursday that it has received a EUR2.4m grant from the German Federal Ministry of Education and Research (BMBF) to support its Phase 2 clinical trial for NOX-A12, a potential treatment for glioblastoma.
This non-dilutive funding, combined with other grants totalling approximately EUR5m, will support the randomised controlled study evaluating NOX-A12 in combination with bevacizumab.
The Phase 2 trial, approved by the US Food and Drug Administration (FDA) and the German regulator, aims to optimise the dosing regimen and assess the efficacy of the combination therapy.
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
TME Pharma secures EUR2.4m grant for NOX-A12 Phase 2 trial
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Johnson & Johnson reports strong Phase 3 results for TREMFYA in Crohn's Disease
Kind Pharmaceutical's AND017 receives US FDA Orphan Drug Designation
RiboX Therapeutics' RXRG001 Phase I/IIa Study IND application receives US FDA approval
Modalis Therapeutics receives Orphan Drug Designation for MDL-101
EpiVax and CUBRC receive USD2m contract from US FDA
U.P. Oncolytics' oncolytic virus-based therapy granted US FDA Orphan Drug designation
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service